Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells

Jessica K Mandula; Paulo C Rodriguez

doi:10.1016/j.ccell.2022.04.017

Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells

Cancer Cell. 2022 Jun 13;40(6):597-599. doi: 10.1016/j.ccell.2022.04.017. Epub 2022 May 19.

Authors

Jessica K Mandula¹, Paulo C Rodriguez²

Affiliations

¹ Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
² Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. Electronic address: paulo.rodriguez@moffitt.org.

PMID: 35594864
DOI: 10.1016/j.ccell.2022.04.017

Abstract

In this issue of Cancer Cell, Long et al. demonstrate that tumors can reprogram erythroid progenitors into myeloid-erythroid cells that promote immunosuppression. Erythroid-differentiated myeloid cells (EDMCs) expand in cancer-bearing individuals, resemble the functionality of myeloid-derived suppressor cells (MDSCs), and correlate with poor response to immune-checkpoint inhibitors (ICIs) and tumor-related anemia.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Immune Tolerance
Immunosuppression Therapy
Myeloid Cells
Myeloid-Derived Suppressor Cells*
Neoplasms* / pathology

Abstract

Publication types

MeSH terms

Grants and funding